Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.65 |
| ▸ | AR | P10275 | 8/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503883 | 0.84 | PGR (0.56) | PGRARNR3C1NR3C2 | |
| SCHEMBL5496654 | 0.80 | PGR (0.56) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL4189738 | 0.79 | PGR (1.00) | PGRARNR3C1NR3C2 | |
| SCHEMBL4172186 | 0.78 | PGR (0.66) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5495706 | 0.77 | PGR (0.43) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5499012 | 0.76 | PGR (0.41) | PGRAR | |
| SCHEMBL5498189 | 0.74 | PGR (0.47) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5515154 | 0.73 | NR3C1 (0.44) | PGRARNR3C1NR3C2ESR1 | |
| SCHEMBL5502164 | 0.73 | PGR (0.43) | PGRARNR3C1NR3C2 | |
| SCHEMBL5502698 | 0.72 | PGR (0.50) | PGRARNR3C1NR3C2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | claimed |
| CN-101018552-A | Intracellular receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-08-15 | — | — | CN | claimed |
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| CN-101018552-A | Intracellular receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | PGR 953/4885AR 486/4885NR3C1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.